All information is correct at the time of publication.
Date published: 1 January 2026
Click on the links in the table for more information about the disease each vaccine protects against.
| Age due | Diseases protected against | Vaccine and name | Usual site | ||
|---|---|---|---|---|---|
|
8 weeks old |
DTaP/IPV/Hib/ HepB (6-in-1) |
Infanrix hexa® or Vaxelis® |
Thigh |
||
| Meningococcal group B (MenB) |
MenB |
Bexsero® |
Thigh |
||
| Rotavirus gastroenteritis |
Rotavirus |
Rotarix® |
By mouth |
||
| 12 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh | |
| Meningococcal group B | MenB | Bexero® | Thigh | ||
| Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth | ||
|
16 weeks old |
Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh | |
| Pneumococcal | PCV 13 | Prevenar 13®1 | Thigh | ||
| 12 months old | |||||
| Pneumococcal | PCV 13 | Prevenar 13®1 | Upper arm/ thigh | ||
| Meningococcal group B | MenB | Bexsero® | Thigh | ||
| Measles, mumps and rubella | MMRV | ProQuad® or Priorix-Tetra® | Upper arm/thigh | ||
| 18 months old | Born before 1 July 2024 | Born on or after 1 July 2024 | |||
| No appointment | Measles, mumps, rubella and varicella | MMRV | ProQuad® or Priorix-Tetra® | Upper arm/thigh | |
| Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Upper arm/thigh | ||
| 22 and 3 years old and all school aged children | Influenza (annually from September) | Live attenuated influenza vaccine | Fluenz®3 | Both nostrils | |
| 3 years 4 months old | Born before 1 January 2025 | Born on or after 1 January 2025 | |||
| Diphtheria, tetanus, pertussis and polio | Diphtheria, tetanus, pertussis and polio | dTaP/IPV (4-in-1) | Repevax® | Upper arm | |
| Measles, mumps, rubella and varicella | No MMRV vaccine | MMRV | ProQuad® or Priorix-Tetra® | Upper arm | |
| School year 8 (12 to 13 year olds) |
Cancers and genital warts caused by specific human papillomavirus (HPV) types | HPV4 (one dose) | Gardasil 9® | Upper arm | |
| School year 9 (13 and 14 year olds) |
Tetanus, diphtheria and polio | Td/IPV (3-in-1) (check MMR status) | Revaxis® | Upper arm | |
| Meningococcal groups A, C, W and Y | MenACWY | Nimenrix® or MenQuadfi® | Upper arm | ||
| 65 years of age and older | Influenza (annually) | Inactivated influenza vaccine |
Adjuvanted trivalent influenza vaccine (aTIV) or Cell-based trivalent influenza vaccine (TIVc)5 |
Upper arm | |
| 65 years of age | Pneumococcal | PPV23 or PCV206 | Pneumovax 23® or Prevenar 20® | Upper arm | |
|
65 years old and 70 to 79 years old (plus people from age 18 with severe immunosuppression) |
Shingles | Shingles | Shingrix® | Upper arm | |
| 75 years old | Respiratory Syncytial Virus (RSV) | RSV | Abrysvo® | Upper arm | |
1 Refer to the Green Book Chapter: Pneumococcal - table 25.3 (external site) for babies with asplenia, splenic dysfunction, complement disorder or severely immunocompromised.
2 Children must be 2 years old by 31 August to receive influenza vaccine in the routine programme in autumn/winter.
3 If Fluenz® is unsuitable, use inactivated flu vaccine.
4 Check the relevant chapter of the Green Book for individuals requiring a 3-dose schedule.
5 Only use TIVc if no aTIV stock is available or if aTIV is unsuitable.
6 PCV20 is expected to replace PPV23 in early 2026.
| Target group | Age and schedule | Disease | Vaccines |
|---|---|---|---|
| Babies born to hepatitis B infected mothers |
At birth and 1 month old1 |
Hepatitis B | Hepatitis B vaccines (Engerix B® / HBvaxPRO®) |
| Infants in areas of the country with TB incidence >= 40/100,000 | From birth | Tuberculosis | BCG® |
| Infants with a parent or grandparent born in a high incidence country2 | From birth | Tuberculosis | BCG® |
| People in a risk group for influenza3 | From 6 months to 64 years | Influenza | Age-appropriate flu vaccine3 |
| Pregnant women | From 16 weeks of pregnancy | Pertussis |
Tdap (ADACEL®) If ADACEL® is unavailable or contraindicated, administer dTaP/IPV (Repevax®) |
| From 28 weeks of pregnancy | Respiratory syncytial virus (RSV) | Abrysvo® | |
| At any stage in pregnancy during the flu season | Influenza | Recommended inactivated flu vaccine3 | |
| Gay, bisexual and other men who have sex with men |
45 years of age and under4 |
HPV4 | Gardasil 9® |
| People at increased risk of mpox5 | Based on risk | Mpox | Imvanex® |
| People at increased risk of gonorrhoea5 | Based on risk | Gonorrhoea | Bexsero® |
1 In addition to hexavalent vaccine (Infanrix hexa or Vaxelis) given at 8, 12, 16 weeks and 18 months. Take blood for HBsAg to exclude infection at 12 to 18 months.
2 Where the annual incidence of TB is >= 40/100,000 see the WHO country profile
3 Refer to annual flu Welsh Health Circular (external site) for eligibility criteria and vaccine recommendations.
4 Check the Green Book Chapter: HPV (external site) for individuals requiring a 1, 2 or 3 dose schedule.
5A sexual health clinician will assess individuals attending the sexual health clinic and advise vaccination if required.
| Medical condition | Diseases protected against | Vaccines required2 |
|---|---|---|
|
Asplenia, splenic dysfunction (Including people with coeliac disease who have splenic dysfunction, and all haemoglobinopathies such as homozygous sickle cell disease) Complement disorder (including people receiving complement inhibitor therapy |
MenACWY Annual flu vaccine5 |
|
| Cochlear implants, cerebrospinal fluid leaks | Pneumococcal | PPV23 or PCV20 (from two years of age)4 |
| Chronic respiratory and heart conditions (such as moderate to severe asthma, chronic pulmonary disease, and heart failure)2 |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
| Chronic neurological conditions (such as Parkinson’s or motor neurone disease, or learning disability) |
Pneumococcal (only if the individual is also at increased risk of aspiration) |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
| Diabetes | PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
|
Chronic kidney disease (CKD) |
Pneumococcal (stage 4 and 5 CKD) Influenza (stage 3, 4 and 5 CKD) Hepatitis B (stage 4 and 5 CKD) |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis B |
| Chronic liver conditions | Pneumococcal Influenza Hepatitis A & B |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis A & Hepatitis B |
| Haemophilia | Hepatitis A & B | Hepatitis A & Hepatitis B |
| Immunosuppression due to disease or treatment6 | Pneumococcal Influenza Shingles |
PCV13 or PCV20 (up to two years of age)3 PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Shingrix (aged 18 years and over) |
1 The list is not exhaustive. Other vaccines may be recommended for certain individuals.
2 Check relevant chapter of the Green Book for specific schedule and for further detail.
3 See table 25.3 – Summary of vaccine and doses for at-risk patients in the Green Book Chapter: Pneumococcal (external site) for further information.
4 Refer to the Green Book Chapter: Pneumococcal (external site) for detailed guidance on vaccine recommendations for this clinical risk group. PCV20 is expected to replace PPV23 in late 2025 or early 2026.
5 From six months of age.
6 Consider annual influenza vaccination for household members and those who care for people with these conditions.